Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States.
Front Immunol. 2019 Jul 24;10:1749. doi: 10.3389/fimmu.2019.01749. eCollection 2019.
Among the top priorities of the HIV field is the search for therapeutic interventions that can lead to sustained antiretroviral therapy (ART)-free HIV remission. Although the majority of HIV-infected persons will experience rapid viral rebound after ART interruption, there are rare individuals, termed post-treatment controllers (PTCs), who demonstrate sustained virologic suppression for months or years after treatment cessation. These individuals are considered an ideal example of durable HIV control, with direct implications for HIV cure research. However, understanding of the mechanisms behind the capacity of PTCs to control HIV remains incomplete. This is in part due to the scarcity of PTCs identified through any one research center or clinical trial, and in part because of the limited scope of studies that have been performed in these remarkable individuals. In this review, we summarize the results of both clinical and basic research studies of PTCs to date, explore key differences between PTCs and HIV spontaneous controllers, examine potential mechanisms of post-treatment control, and discuss unanswered questions and future research directions in this field.
HIV 领域的当务之急之一是寻找能够实现持续抗逆转录病毒治疗(ART)停药后 HIV 缓解的治疗干预措施。尽管大多数 HIV 感染者在停止 ART 后会经历快速病毒反弹,但有少数被称为治疗后控制者(PTC)的个体在停止治疗后数月或数年仍能持续抑制病毒。这些个体被认为是 HIV 持续控制的理想范例,对 HIV 治愈研究具有直接意义。然而,对 PTC 控制 HIV 能力背后机制的理解仍不完整。这部分是由于通过任何一个研究中心或临床试验确定的 PTC 数量稀少,部分是由于对这些杰出个体进行的研究范围有限。在这篇综述中,我们总结了迄今为止对 PTC 的临床和基础研究的结果,探讨了 PTC 与 HIV 自发控制者之间的关键差异,检查了治疗后控制的潜在机制,并讨论了该领域未解决的问题和未来的研究方向。